- ►hopkinsmedicine.org [PDF] SE Kahn, SM Haffner, MA Heise, WH Herman, … - New England Journal of Medicine, 2006 - content.nejm.org From the Veterans Affairs Puget Sound Health Care System and University of
Washington, Seattle (SEK); University of Texas Health Science Center at San An
tonio, San Antonio (SMH); GlaxoSmith Kline, King of Prussia, PA (MAH, BGK, ... Cited by 769 - Related articles - BL Direct - All 30 versions
- Free from Publisher RA DeFronzo, RE Ratner, J Han, DD Kim, MS … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study
at 82 US sites was performed with 336 randomized patients. In all, 272 patients
completed the study. The intent-to-treat population baseline was 53 ± 10 ... Cited by 637 - Related articles - All 6 versions
- Free from Publisher DM Kendall, MC Riddle, J Rosenstock, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg),
−0.6 ± 0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs.
placebo), yielding placebo-adjusted reductions of −1.0% (10 μg) and ... Cited by 543 - Related articles - All 11 versions
- ►colfar.com [PDF] - Free from Publisher PA Hollander, L Blonde, R Rowe, AE Mehta, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS— HbA 1c decreased similarly in the inhaled (−0.7%) and subcutaneous
(−0.6%) insulin groups (adjusted treatment group difference: −0.07%, 95% CI
−0.32 to 0.17). HbA 1c <7.0% was achieved in more patients receiving ... Cited by 237 - Related articles - BL Direct - All 21 versions
- Free from Publisher K Hermansen, M Davies, T Derezinski, G … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and
from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of
participants achieved an A1C ≤7.0%, but the proportion achieving this ... Cited by 224 - Related articles - BL Direct - All 9 versions
L Blonde, EJ Klein, J Han, B Zhang, SM Mac, … - Diabetes, Obesity & Metabolism, 2006 - pt.wkhealth.com Results: Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age
56 ± 10 years, weight 99 ± 21 kg, body mass index 34 ± 6 kg/m 2 , A1C 8.3 ±
1.0% (mean ± SD)]. Reduction in A1C from baseline to week 30 [-0.9 ± 0.1% ... Cited by 172 - Related articles - BL Direct - All 6 versions
- ►perioimplantelsalvador.com [PDF] BL Mealey, TW Oates - Journal of Periodontology, 2006 - Am Acad Periodontology Background: The purpose of this review is to provide the reader with practical
knowledge concerning the relationship between diabetes mellitus and periodontal
diseases. Over 200 articles have been published in the English literature ... Cited by 160 - Related articles - BL Direct - All 18 versions
- ►pipex.com [PDF] RR Holman, KI Thorne, AJ Farmer, MJ Davies, … - New England Journal of Medicine, 2007 - content.nejm.org From the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and
Metabolism (RRH, KIT, AJF, JFK, SP, JCL) and the Department of Primary Health
Care (AJF), University of Oxford, Oxford; and the Department of Cardiovas- ... Cited by 134 - Related articles - BL Direct - All 12 versions
- ►diabetesjournals.org D Kim, L MacConell, D Zhuang, PA Kothare, … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—From baseline to week 15, exenatide LAR reduced mean ± SE A1C by
−1.4 ± 0.3% (0.8 mg) and −1.7 ± 0.3% (2.0 mg), compared with +0.4 ± 0.3%
with placebo LAR (P < 0.0001 for both). A1C of ≤7% was achieved by 36 and ... Cited by 128 - Related articles - BL Direct - All 5 versions
- ►annals.org [PDF] B Zinman, BJ Hoogwerf, S Duran Garcia, DR … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Exenatide therapy is effective in combination with metformin or
sulfonylureas for treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are
commonly used, but the efficacy of exenatide with a TZD has not been reported. Cited by 119 - Related articles - BL Direct - All 5 versions
